Daily Sepsis Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
Three mechanistic studies advance sepsis science across host immunity, pathogen regulation, and neurobiology. A Nature Communications study identifies DPEP2 as an immunometabolic brake and demonstrates lipid nanoparticle mRNA therapy to myeloid cells in septic mice; another shows that pneumococcal capsule transcriptional control can drive serotype-specific invasiveness; and a CNS neuroscience study reveals a neuron-intrinsic c-MAF/Slc40a1 axis that suppresses ferroptosis in sepsis-associated encephalopathy.
Research Themes
- Immunometabolic regulation and eicosanoid signaling in sepsis
- Pathogen capsule transcriptional control and vaccine-driven adaptation
- Ferroptosis and neuroinflammation in sepsis-associated encephalopathy
Selected Articles
1. DPEP2 suppresses hyperinflammation via metabolic reprogramming of macrophages in sepsis.
Integrating patient single-cell and bulk transcriptomics with mouse models, the authors identify DPEP2 as a negative regulator of sepsis hyperinflammation. EGR1 represses Dpep2, reducing enzymatic cleavage of LTD4 and shunting eicosanoid flux toward PGE2, amplifying NF-κB signaling; lipid nanoparticle delivery of Dpep2 mRNA to monocytes/macrophages mitigated inflammation, organ injury, and improved survival in septic mice.
Impact: Reveals a patient-informed immunometabolic mechanism that is therapeutically actionable and demonstrates a translatable LNP mRNA strategy targeting myeloid cells in sepsis.
Clinical Implications: DPEP2 may serve as a biomarker of hyperinflammation and a therapeutic target; mRNA-based augmentation of DPEP2 or modulation of the LTD4–PGE2 axis could be explored in early-phase trials.
Key Findings
- DPEP2 expression is reduced in septic patient monocytes/macrophages and inversely correlates with disease severity and outcomes.
- EGR1 represses Dpep2 transcription, reducing DPEP2-mediated LTD4 cleavage and redirecting eicosanoid metabolism toward PGE2, amplifying NF-κB signaling.
- Macrophage-specific Dpep2 loss exacerbates inflammation and organ injury in septic mice, while LNP-mediated Dpep2 mRNA delivery mitigates injury and improves survival.
Methodological Strengths
- Integration of patient single-cell and bulk RNA-seq with mechanistic in vivo models
- Therapeutic rescue using lipid nanoparticle mRNA delivery to monocytes/macrophages
Limitations
- Preclinical mouse models; human interventional data are lacking
- Safety, dosing, and off-target effects of myeloid-targeted LNP mRNA require evaluation
Future Directions: Validate DPEP2 as a prognostic/therapeutic biomarker in prospective cohorts; test DPEP2 augmentation and leukotriene/prostaglandin pathway modulators in phase I/II trials.
Sepsis-induced excessive inflammation contributes to mortality, but restricting hyperinflammation in sepsis remains challenging. Here, we identify dipeptidase 2 (DPEP2) as an immunotherapeutic target in sepsis by integrating single-cell and bulk RNA sequencing data from septic patients. In patients with sepsis, peripheral monocytes/macrophages have reduced DPEP2 expression, with DPEP2 levels negatively correlating with inflammation severity, disease progression, and clinical outcomes. In vitro, Dpep2 knockdown enhances macrophage-mediated
2. Transcriptional regulation of the pneumococcal capsule can dictate serotype-specific infection.
The authors show that subtle, natural variations in the regulatory region controlling the cps operon produce serotype-specific transcriptional programs that alter capsule expression and infection outcomes. This mechanism provides a rapid path for pneumococci to adapt to vaccine pressure without relying on recombination.
Impact: Shifts the paradigm from capsule chemistry alone to transcriptional regulation as a determinant of invasiveness, with implications for surveillance and vaccine design.
Clinical Implications: Surveillance should incorporate regulatory-region genotyping to anticipate shifts in invasiveness; vaccine strategies may need to consider regulating capsule expression, not just composition.
Key Findings
- Serotype-specific infection outcomes can arise from natural sequence variation in the cps regulatory region, not only capsule chemistry.
- Distinct transcriptional control of the cps locus produces differences in capsule expression linked to colonization versus invasiveness.
- This mechanism offers a rapid adaptive route to vaccine pressure without requiring genetic recombination.
Methodological Strengths
- Mechanistic linkage between regulatory sequence variation and cps transcription
- Functional demonstration connecting capsule expression programs to infection phenotypes
Limitations
- Clinical translation and generalizability across >100 serotypes require broader validation
- Human outcome associations were not directly studied
Future Directions: Integrate cps regulatory-region surveillance into population studies; model vaccine-driven selection on regulatory variants; develop diagnostics that detect high-risk regulatory haplotypes.
Streptococcus pneumoniae (the pneumococcus) is a human bacterial pathogen and the major cause of bacterial pneumonia, which can further develop into sepsis. The pneumococcus has evolved over 107 antigenically-distinct serotypes that are defined by the chemical composition of its capsule; its major virulence factor and the main protective antigen within the vaccine. Owing to its capsule diversification, certain serotypes are known for being more effective at either colonization or invasiveness. It has historically been accepted that these differences are due to the chemical properties
3. c-MAF Transcriptionally Activates Slc40a1 to Repress Ferroptosis in Sepsis-Associated Encephalopathy.
Using CLP-induced sepsis models with neuron-specific AAV9 manipulations, the study shows that c-MAF directly drives Slc40a1 (ferroportin) transcription to restrain neuronal ferroptosis, reducing lipid peroxidation and iron deposition and improving cognition and survival. Silencing Slc40a1 abrogates c-MAF’s protective effects, establishing a causal c-MAF/Slc40a1 axis in SAE.
Impact: Defines a neuron-intrinsic, targetable ferroptosis pathway in sepsis-associated encephalopathy with strong genetic and functional evidence.
Clinical Implications: Supports testing ferroptosis inhibitors and strategies enhancing neuronal iron export as candidate therapies for SAE; Slc40a1 expression could inform patient stratification.
Key Findings
- Slc40a1 is downregulated in hippocampal neurons after CLP; neuronal knockdown of Slc40a1 or c-Maf worsens cognition and ferroptosis.
- Overexpression of c-Maf or Slc40a1 reduces lipid peroxidation and iron deposition, improving survival and cognitive outcomes.
- c-MAF binds the Slc40a1 promoter to drive its transcription; Slc40a1 silencing negates c-MAF’s anti-ferroptotic effects.
Methodological Strengths
- Neuron-specific genetic manipulation with AAV9 in a validated CLP sepsis model
- Mechanistic validation via dual-luciferase and ChIP assays linking c-MAF to Slc40a1
Limitations
- Preclinical mouse data; human validation and biomarker studies are needed
- Focus on neuronal compartment; contributions from glia or systemic factors remain to be defined
Future Directions: Translate findings to human biospecimens (CSF/brain tissue) and pilot trials of ferroptosis-modulating agents in SAE; explore combinatorial strategies with anti-inflammatory therapies.
BACKGROUND: Ferroptosis, an iron-dependent programmed cell death driven by lipid peroxidation, has emerged as a potential contributor to sepsis-associated encephalopathy (SAE). However, the relationship between ferroptosis and cognitive deficits following sepsis needs to be further elucidated. METHODS: Transcriptome sequencing was employed to identify solute carrier family 40 member 1 (Slc40a1) as a candidate ferroptosis-related gene in the hippocampus of septic mice. The SAE mouse model was established via cecal ligation and perforation (CLP) after treatment with recombinant adeno-associated virus 9 (AAV9)-CaMKII to knock down or overexpress musculoaponeurotic fibrosarcoma (c-Maf) or Slc40a1. We assessed cognitive performance, Nissl staining, and ferroptosis-associated parameters. Dual-luciferase reporter gene assays and chromatin immunoprecipitation assays were performed to illuminate the mechanism by which c-MAF transcriptionally activates Slc40a1. RESULTS: Hippocampal neurons of mice subjected to CLP showed downregulation of Slc40a1. Neuron-specific knockdown of Slc40a1 or c-Maf deteriorated sepsis-induced cognitive impairment, oxidative stress, and ferroptosis. Conversely, overexpression of Slc40a1 or c-Maf attenuated acute mortality and cognitive impairment following CLP, hampered lipid peroxidation and iron deposition, and enhanced antioxidant capacity. Moreover, Slc40a1 silencing neutralized the anti-ferroptotic property of c-Maf in SAE. Mechanistically, c-MAF was found to directly bind to the Slc40a1 promoter and facilitate its transcription. CONCLUSIONS: Our findings suggest that c-MAF/Slc40a1 may represent a promising prevention target for SAE.